Endo International plc (ENDP) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues:
Vasostrict®	253.7	901.7	785.6	531.7	453.8	416.3
Branded Pharmaceuticals	851.1	893.6	781.8	855.4	862.8	86.2
XIAFLEX®	438.7	432.3	316.2	327.6	264.6	282.6
Sterile Injectables	589.6	1,266.1	1,238.8	1,063.1	929.6	750.5
Other	185.7			136.5	436.3	1,933.3
Total revenues	2,318.9	2,993.2	2,903.1	2,914.4	2,947.1	3,468.9	4,010.3	3,268.7
Revenue growth [+]	-22.5%	3.1%	-0.4%	-1.1%	-15.0%	-13.5%	22.7%	37.3%
Vasostrict®	-71.9%	14.8%	47.8%	17.2%	9.0%
Branded Pharmaceuticals	-4.8%	14.3%	-8.6%	-0.9%	900.8%
XIAFLEX®	1.5%	36.7%	-3.5%	23.8%	-6.4%
Sterile Injectables	-53.4%	2.2%	16.5%	14.4%	23.9%
Generic Pharmaceuticals	7.4%	-5.4%	-11.0%	-13.1%	-33.9%
Cost of goods sold	1,092.5	1,221.1	1,442.5	1,569.3	1,631.7	2,228.5	2,635.0	2,075.7
Gross profit	1,226.4	1,772.1	1,460.6	1,345.0	1,315.4	1,240.3	1,375.3	1,193.1
Gross margin	52.9%	59.2%	50.3%	46.2%	44.6%	35.8%	34.3%	36.5%
Selling, general and administrative	777.2	861.8	698.5	632.4	646.0	629.9	770.7	741.3
Research and development	128.0	123.4	125.6	130.7	185.8	172.1	183.4	102.2
Other operating expenses	203.0	27.5		-228.4	13.8	255.4
EBITDA [+]	509.8	1,216.5	1,155.3	1,423.2	1,193.4	1,166.7	1,404.5	982.3
EBITDA growth	-58.1%	5.3%	-18.8%	19.3%	2.3%	-16.9%	43.0%	22.8%
EBITDA margin	22.0%	40.6%	39.8%	48.8%	40.5%	33.6%	35.0%	30.1%
Depreciation	54.3	457.1	518.8	612.9	101.4	210.0	106.8	71.5
EBITA	455.5	759.4	636.5	810.3	1,092.0	956.8	1,297.7	910.9
EBITA margin	19.6%	25.4%	21.9%	27.8%	37.1%	27.6%	32.4%	27.9%
Amortization of intangibles	337.3				622.3	773.8	876.5	561.3
EBIT [+]	118.2	759.4	636.5	810.3	469.7	183.0	421.2	349.6
EBIT growth	-84.4%	19.3%	-21.5%	72.5%	156.7%	-56.6%	20.5%	-25.4%
EBIT margin	5.1%	25.4%	21.9%	27.8%	15.9%	5.3%	10.5%	10.7%
Non-recurring items [+]	2,690.6	777.2	151.2	480.0	938.9	1,212.5	3,892.7	1,283.0
Asset impairment	2,142.7	415.0	120.3	526.1	916.9	1,154.4	3,781.2	1,140.7
Legal settlement	478.7	345.5	-19.0				24.0	37.1
Interest expense	349.8	562.4	532.9	538.7	521.7	488.2	452.7	373.2
Interest expense	349.8	562.4	532.9	538.7	521.7	488.2	452.7	373.2
Other income (expense), net [+]	34.1	33.5	21.1	-136.5	52.0	34.7	0.3	-131.2
Litigation settlement				11.2	13.8	186.0
Gain (loss) on debt retirement		-13.8		119.8		-51.7		-67.5
Other	34.1	19.8	21.1	-16.7	52.0	-17.0	5.3	1.2
Pre-tax income	-2,888.1	-546.6	-26.5	-344.9	-938.8	-1,483.0	-3,923.9	-1,437.9
Income taxes	21.5	22.5	-274.0	15.7	22.9	-250.3	-700.1	-1,137.5
Tax rate			1033.2%			16.9%	17.8%	79.1%
Minority interest							0.0	-0.3
Earnings from continuing ops	-2,909.6	-569.1	247.5	-360.6	-961.8	-1,232.7	-3,223.8	-300.1
Earnings from discontinued ops							-123.3	-1,194.9
Net income	-2,923.1	-613.2	183.9	-422.6	-1,031.5	-2,035.4	-3,347.1	-1,495.0
Net margin	-126.1%	-20.5%	6.3%	-14.5%	-35.0%	-58.7%	-83.5%	-45.7%

Basic EPS [+]	($12.39)	($2.44)	$1.08	($1.60)	($4.29)	($5.52)	($14.48)	($1.52)
Growth	406.8%	-326.5%	-167.7%	-62.9%	-22.2%	-61.9%	850.9%	-482.5%
Diluted EPS [+]	($12.39)	($2.44)	$1.06	($1.60)	($4.29)	($5.52)	($14.48)	($1.52)
Growth	406.8%	-330.8%	-166.4%	-62.9%	-22.2%	-61.9%	850.9%	-508.1%

Shares outstanding (basic) [+]	234.8	232.8	229.3	226.1	224.0	223.2	222.7	197.1
Growth	0.9%	1.5%	1.4%	0.9%	0.3%	0.2%	13.0%	34.2%
Shares outstanding (diluted) [+]	234.8	232.8	233.7	226.1	224.0	223.2	222.7	197.1
Growth	0.9%	-0.4%	3.4%	0.9%	0.3%	0.2%	13.0%	25.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.